TY - JOUR
T1 - Clinical Impact of Pretransplantation Physical Function on Transplantation after Allogeneic Hematopoietic Cell Transplantation in Older Adults
AU - Gomyo, Ayumi
AU - Kimura, Shun ichi
AU - Suzuki, Junko
AU - Ishikawa, Takuto
AU - Meno, Tomohiro
AU - Matsuoka, Akari
AU - Nakamura, Yuhei
AU - Kawamura, Masakatsu
AU - Kawamura, Shunto
AU - Takeshita, Junko
AU - Yoshino, Nozomu
AU - Misaki, Yukiko
AU - Yoshimura, Kazuki
AU - Okada, Yosuke
AU - Akahoshi, Yu
AU - Tamaki, Masaharu
AU - Kusuda, Machiko
AU - Kameda, Kazuaki
AU - Wada, Hidenori
AU - Sato, Miki
AU - Tanihara, Aki
AU - Sekine, Kazuki
AU - Nakasone, Hideki
AU - Kako, Shinichi
AU - Kanda, Yoshinobu
N1 - Publisher Copyright:
© 2023 The American Society for Transplantation and Cellular Therapy
PY - 2023/11
Y1 - 2023/11
N2 - Clinical research regarding the impact of pretransplantation physical function on transplantation outcomes in older adults remains limited. We retrospectively reviewed the charts of 150 consecutive patients age >55 years who underwent their first allogeneic hematopoietic cell transplantation (HCT) at our center between 2010 and 2021. We evaluated the clinical impact of pretransplantation physical function, including hand grip strength (HGS), knee extension strength (KES), and distance covered in a 6-minute walk test (6MWT), along with other clinical factors, on transplantation outcomes such as overall survival (OS), nonrelapse mortality (NRM), and cumulative incidence of disease relapse (CIR). There was no difference in OS, NRM, or CIR among the 3 age groups studied (56 to 60 years, 61 to 65 years, and 66 to 70 years). With regard to physical function tests, we divided the study patients into 2 groups based on the median HGS, KES, and 6MWT values: higher physical function and lower physical function groups. Because there were significant differences in HGS and KES between male and female patients, sex-specific threshold values were used. In a univariate analysis, OS tended to be better in the higher physical function group compared with the lower physical function group (4-year OS, 42.0% versus 32.0% in HGS, P =.14; 44.8% versus 37.8% in KES, P =.17; 46.7% versus 30.5% in 6MWT, P =.099). NRM was significantly lower in the higher physical function group (4-year NRM, 25.5% versus 39.9% in HGS, P =.045; 17.7% versus 38.0% in KES, P =.005; 22.5% versus 43.4% in 6MWT, P =.033). There was no significant difference in CIR between the higher and lower physical function groups (4-year CIR, 34.6% versus 28.7% in HGS, P =.38; 38.5% versus 25.8% in KES, P =.20; 33.0% versus 27.0% in 6MWT, P =.42). In multivariate analysis, the higher KES group (hazard ratio [HR],.54; 95% confidence interval [CI],.32 to.90) was significantly associated with better OS, as were female sex (HR,.48; 95% CI,.26 to.89) and low/intermediate Disease Risk Index (HR, 3.59; 95% CI, 2.04 to 6.31). Higher KES (HR,.37; 95% CI,.17 to.83) and female sex (HR.36; 95% CI,.13 to.998) were significantly associated with a reduced risk of NRM. Higher HGS and higher 6MWT tended to be associated with a reduced risk of NRM, but this trend was not statistically significant. Pretransplantation physical function, particularly the strength of the lower extremities, but not chronological age, is associated with NRM and OS after allogeneic HCT in adults age >55 years.
AB - Clinical research regarding the impact of pretransplantation physical function on transplantation outcomes in older adults remains limited. We retrospectively reviewed the charts of 150 consecutive patients age >55 years who underwent their first allogeneic hematopoietic cell transplantation (HCT) at our center between 2010 and 2021. We evaluated the clinical impact of pretransplantation physical function, including hand grip strength (HGS), knee extension strength (KES), and distance covered in a 6-minute walk test (6MWT), along with other clinical factors, on transplantation outcomes such as overall survival (OS), nonrelapse mortality (NRM), and cumulative incidence of disease relapse (CIR). There was no difference in OS, NRM, or CIR among the 3 age groups studied (56 to 60 years, 61 to 65 years, and 66 to 70 years). With regard to physical function tests, we divided the study patients into 2 groups based on the median HGS, KES, and 6MWT values: higher physical function and lower physical function groups. Because there were significant differences in HGS and KES between male and female patients, sex-specific threshold values were used. In a univariate analysis, OS tended to be better in the higher physical function group compared with the lower physical function group (4-year OS, 42.0% versus 32.0% in HGS, P =.14; 44.8% versus 37.8% in KES, P =.17; 46.7% versus 30.5% in 6MWT, P =.099). NRM was significantly lower in the higher physical function group (4-year NRM, 25.5% versus 39.9% in HGS, P =.045; 17.7% versus 38.0% in KES, P =.005; 22.5% versus 43.4% in 6MWT, P =.033). There was no significant difference in CIR between the higher and lower physical function groups (4-year CIR, 34.6% versus 28.7% in HGS, P =.38; 38.5% versus 25.8% in KES, P =.20; 33.0% versus 27.0% in 6MWT, P =.42). In multivariate analysis, the higher KES group (hazard ratio [HR],.54; 95% confidence interval [CI],.32 to.90) was significantly associated with better OS, as were female sex (HR,.48; 95% CI,.26 to.89) and low/intermediate Disease Risk Index (HR, 3.59; 95% CI, 2.04 to 6.31). Higher KES (HR,.37; 95% CI,.17 to.83) and female sex (HR.36; 95% CI,.13 to.998) were significantly associated with a reduced risk of NRM. Higher HGS and higher 6MWT tended to be associated with a reduced risk of NRM, but this trend was not statistically significant. Pretransplantation physical function, particularly the strength of the lower extremities, but not chronological age, is associated with NRM and OS after allogeneic HCT in adults age >55 years.
KW - Allogeneic hematopoietic cell transplantation
KW - Hand grip strength
KW - Knee extension strength
KW - Older adults
KW - Physical function
KW - Six-minute walk test
UR - http://www.scopus.com/inward/record.url?scp=85173236790&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2023.08.023
DO - 10.1016/j.jtct.2023.08.023
M3 - Article
C2 - 37643718
AN - SCOPUS:85173236790
SN - 2666-6375
VL - 29
SP - 721.e1-721.e8
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 11
ER -